Literature DB >> 10594669

Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat.

M J Millan1, M Brocco, A Gobert, F Joly, K Bervoets, J Rivet, A Newman-Tancredi, V Audinot, S Maurel.   

Abstract

In the present study, the comparative mechanisms of action of phencyclidine (PCP) and amphetamine were addressed employing the parameter of locomotion in rats. PCP-induced locomotion (PLOC) was potently blocked by the selective serotonin (5-HT)2A vs. D2 antagonists, SR46349, MDL100,907, ritanserin and fananserin, which barely affected amphetamine-induced locomotion (ALOC). In contrast, the selective D2 vs. 5-HT2A antagonists, eticlopride, raclopride and amisulpride, preferentially inhibited ALOC vs. PLOC. The potency of these drugs and 12 multireceptorial antipsychotics in inhibiting PLOC vs. ALOC correlated significantly with affinities at 5-HT2A vs. D2 receptors, respectively. Amphetamine and PCP both dose dependently increased dialysate levels of dopamine (DA) and 5-HT in the nucleus accumbens, striatum and frontal cortex (FCX) of freely moving rats, but PCP was proportionally more effective than amphetamine in elevating levels of 5-HT vs. DA in the accumbens. Further, whereas microinjection of PCP into the accumbens elicited locomotion, its introduction into the striatum or FCX was ineffective. The action of intra-accumbens PCP, but not intra-accumbens amphetamine, was abolished by SR46349 and clozapine. Parachloroamphetamine, which depleted accumbens pools of 5-HT but not DA, likewise abolished PLOC without affecting ALOC. In contrast, intra-accumbens 6-hydroxydopamine (6-OHDA), which depleted DA but not 5-HT, abolished ALOC but only partially attenuated PLOC. In conclusion, PLOC involves (indirect) activation of accumbens-localized 5-HT2A receptors by 5-HT. PLOC is, correspondingly, more potently blocked than ALOC by antipsychotics displaying marked affinity at 5-HT2A receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10594669     DOI: 10.1046/j.1460-9568.1999.00858.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  39 in total

1.  F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.

Authors:  R Depoortère; L Bardin; A L Auclair; M S Kleven; E Prinssen; F Colpaert; B Vacher; A Newman-Tancredi
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

2.  Quantitative trait locus analysis identifies rat genomic regions related to amphetamine-induced locomotion and Galpha(i3) levels in nucleus accumbens.

Authors:  Marc N Potenza; Edward S Brodkin; Bao-Zhu Yang; Shari G Birnbaum; Eric J Nestler; Joel Gelernter
Journal:  Neuropsychopharmacology       Date:  2008-01-23       Impact factor: 7.853

Review 3.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

4.  ADN-1184 a monoaminergic ligand with 5-HT(6/7) receptor antagonist activity: pharmacological profile and potential therapeutic utility.

Authors:  M Kołaczkowski; P Mierzejewski; P Bieńkowski; A Wesołowska; A Newman-Tancredi
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

5.  Neural basis of the potentiated inhibition of repeated haloperidol and clozapine treatment on the phencyclidine-induced hyperlocomotion.

Authors:  Changjiu Zhao; Tao Sun; Ming Li
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-03-26       Impact factor: 5.067

6.  Effectiveness of lamotrigine in maintaining symptom control in pediatric bipolar disorder.

Authors:  Mani N Pavuluri; David B Henry; Melissa Moss; Tahseen Mohammed; Julie A Carbray; John A Sweeney
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-02       Impact factor: 2.576

7.  NMDA antagonist and antipsychotic actions in cortico-subcortical circuits.

Authors:  Lucila Kargieman; Noemí Santana; Guadalupe Mengod; Pau Celada; Francesc Artigas
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

8.  Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study.

Authors:  Daniel Ecker; Alexander Unrath; Jan Kassubek; Michael Sabolek
Journal:  BMC Neurol       Date:  2009-06-10       Impact factor: 2.474

9.  Ethanol and phencyclidine interact with respect to nucleus accumbens dopamine release: differential effects of administration order and pretreatment protocol.

Authors:  Chris Pickering; Pei Pei Chau; Bo Söderpalm; Mia Ericson
Journal:  Front Behav Neurosci       Date:  2010-06-10       Impact factor: 3.558

10.  Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes.

Authors:  Mark J Millan; Sylvie Veiga; Sylvie Girardon; Mauricette Brocco
Journal:  Psychopharmacology (Berl)       Date:  2003-04-30       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.